 -- The Phase 1 portion s of the stud ies are closed for enrollment ; patient trea tment and follow -up for efficacy and safety continues -- EMERYVILLE, Calif., Nov. 02, 2020 GLOBE NEWSWIRE -- Gritstone Oncology, Inc. Nasdaq: GRTS, a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that it has begun dosing patients in the Phase 2 expansion cohorts of the Phase 12 clinical studies for GRANITE and SLATE, its neoantigen-based immunotherapies. 